School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
Institute for Design Informatics, School of Informatics, University of Edinburgh, Edinburgh, UK.
Eur Heart J. 2024 Oct 5;45(37):3837-3849. doi: 10.1093/eurheartj/ehae345.
Many patients are prescribed loop diuretics without a diagnostic record of heart failure. Little is known about their characteristics and prognosis.
Glasgow regional health records (2009-16) were obtained for adults with cardiovascular disease or taking loop diuretics. Outcomes were investigated using Cox models with hazard ratios adjusted for age, sex, socioeconomic deprivation, and comorbid disease (adjHR).
Of 198 898 patients (median age 65 years; 55% women), 161 935 (81%) neither took loop diuretics nor had a diagnostic record of heart failure (reference group), 23 963 (12%) were taking loop diuretics but had no heart failure recorded, 7844 (4%) had heart failure recorded and took loop diuretics, and 5156 (3%) had heart failure recorded but were not receiving loop diuretics. Compared to the reference group, five-year mortality was only slightly higher for heart failure in the absence of loop diuretics [22%; adjHR 1.2 (95% CI 1.1-1.3)], substantially higher for those taking loop diuretics with no record of heart failure [40%; adjHR 1.8 (95% CI 1.7-1.8)], and highest for heart failure treated with loop diuretics [52%; adjHR 2.2 (95% CI 2.0-2.2)].
For patients with cardiovascular disease, many are prescribed loop diuretics without a recorded diagnosis of heart failure. Mortality is more strongly associated with loop diuretic use than with a record of heart failure. The diagnosis of heart failure may be often missed, or loop diuretic use is associated with other conditions with a prognosis similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true.
许多患者在没有心力衰竭诊断记录的情况下被开了噻嗪类利尿剂。人们对他们的特征和预后知之甚少。
获取了 2009 年至 2016 年期间患有心血管疾病或服用噻嗪类利尿剂的成年人的格拉斯哥地区健康记录。使用 Cox 模型调查了结果,该模型使用年龄、性别、社会经济贫困程度和合并症(调整后的危险比,adjHR)对风险比进行了调整。
在 198898 名患者中(中位年龄 65 岁;55%为女性),161935 名(81%)既未服用噻嗪类利尿剂也未记录心力衰竭(参照组),23963 名(12%)服用噻嗪类利尿剂但未记录心力衰竭,7844 名(4%)记录有心力衰竭并服用噻嗪类利尿剂,5156 名(3%)记录有心力衰竭但未服用噻嗪类利尿剂。与参照组相比,没有噻嗪类利尿剂的心力衰竭患者五年死亡率仅略高[22%;调整后的危险比 1.2(95%CI 1.1-1.3)],而服用噻嗪类利尿剂且没有心力衰竭记录的患者死亡率要高得多[40%;调整后的危险比 1.8(95%CI 1.7-1.8)],心力衰竭患者用噻嗪类利尿剂治疗的死亡率最高[52%;调整后的危险比 2.2(95%CI 2.0-2.2)]。
对于患有心血管疾病的患者,许多人在没有记录心力衰竭诊断的情况下被开了噻嗪类利尿剂。死亡率与噻嗪类利尿剂的使用比与心力衰竭的记录更密切相关。心力衰竭的诊断可能经常被遗漏,或者噻嗪类利尿剂的使用与其他预后与心力衰竭相似的情况有关,或者不适当使用噻嗪类利尿剂会增加死亡率;所有这些情况都有可能。